Neuren Secures US FDA Fast Track for NNZ-2591 in Phelan McDermid Syndrome

Neuren Pharmaceuticals (ASX: NEU) has received a significant regulatory boost with the United States Food and Drug Administration granting Fast Track designation for its drug candidate NNZ-2591 in the treatment of Phelan McDermid syndrome. The designation is designed to accelerate the development and review of therapies for serious conditions where there are currently no approved treatments.

Phelan McDermid syndrome, also known as 22q13 deletion syndrome, is a rare genetic condition caused by changes in the SHANK3 gene. The disorder severely affects quality of life, with symptoms ranging from intellectual and developmental delay to absent speech, autism traits, low muscle tone and epilepsy. There are no medications currently approved for this condition.

Neuren recently initiated the “Koala” Phase 3 clinical trial to evaluate NNZ-2591 in children aged 3 to 12 with Phelan McDermid syndrome. The FDA has already agreed on the trial design and endpoints that could support a future New Drug Application, paving the way for potential commercial approval if the trial proves successful.

“This Fast Track designation comes at a meaningful time, as we mark Phelan McDermid Syndrome Awareness Day,” said Neuren CEO Jon Pilcher. “It reflects the FDA’s recognition of the urgent need for treatment options and supports our goal of bringing meaningful change to families affected by this condition.”

The Koala study is the first ever Phase 3 trial for Phelan McDermid syndrome, reinforcing Neuren’s leading position in the development of therapies for rare paediatric neurological disorders. Fast Track status offers a range of regulatory benefits, including more frequent interactions with the FDA, eligibility for accelerated approval and rolling review of data.

This is the third Fast Track designation secured by Neuren for NNZ-2591, which is also being developed for Angelman and Pitt Hopkins syndromes. All three indications have also been granted orphan drug designation in both the United States and European Union.

Neuren’s previous success with DAYBUE, a treatment for Rett syndrome now approved in the United States and Canada, has set a strong precedent. DAYBUE is commercialised under licence by Acadia Pharmaceuticals, and the company is following a similar clinical path with NNZ-2591.

With Fast Track status now in place, Neuren is well positioned to advance NNZ-2591 through its clinical program and deliver a potential first-in-class therapy for a condition that currently has no available treatment options.